AbbVie (ABBV) Competitors

AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Is ABBV or AMGN more profitable?

Amgen has a net margin of 17.39% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 518.10% beat Amgen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	6.45%	518.10%	13.61%
Amgen	17.39%	176.11%	12.39%

Does the media refer more to ABBV or AMGN?

In the previous week, AbbVie had 78 more articles in the media than Amgen. MarketBeat recorded 131 mentions for AbbVie and 53 mentions for Amgen. Amgen's average media sentiment score of 1.34 beat AbbVie's score of 1.02 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	85 Very Positive mention(s)	7 Positive mention(s)	30 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Amgen	45 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ABBV or AMGN a better dividend stock?

AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.4%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. AbbVie pays out 279.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years and Amgen has increased its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has preferable earnings & valuation, ABBV or AMGN?

AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$56.33B	6.12	$4.28B	$2.35	83.05
Amgen	$33.42B	4.78	$4.09B	$10.96	27.09

Do analysts rate ABBV or AMGN?

AbbVie presently has a consensus price target of $212.81, suggesting a potential upside of 9.04%. Amgen has a consensus price target of $307.27, suggesting a potential upside of 3.50%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.81
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35

Which has more volatility & risk, ABBV or AMGN?

AbbVie has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in ABBV or AMGN?

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbbVie beats Amgen on 14 of the 20 factors compared between the two stocks.